A TP53-mutáció-analízis jelentosége krónikus lymphocytás leukaemiában

Fésüs Viktória, Marosvári Dóra, Kajtár Béla, Király Péter Attila, J. Demeter, Gurbity Pálfi Tímea, Egyed Miklós, Plander Márk, Farkas Péter, Mátrai Zoltán, A. Matolcsy, Bödör Csaba

Research output: Article

2 Citations (Scopus)

Abstract

Introduction: In recent years much progress has been made in the therapy of chronic lymphocytic leukaemia, as the new innovative medicine proved to be effective in managing patients carrying TP53 abnormalities. To identify all these patients, it is essential to screen for both forms of TP53 defects, including both 17p deletions and TP53 mutations. Aim: The aim of this study was to determine the frequency of TP53 mutations and their association with 17p deletions in a large Hungarian cohort of 196 patients suffering from chronic lymphocytic leukaemia. Method: We performed mutation analysis of TP53 (exons 3-10) using Sanger sequencing. Results: TP53 mutations were present in 15.8% of patients, half of which were associated with 17p deletion. By analysing both forms, TP53 defect was identified in 25.4% of the patients. Conclusions: Our study demonstrates that by performing a TP53 mutation analysis, an additional 10% of high-risk patients can be detected.

Original languageHungarian
Pages (from-to)220-228
Number of pages9
JournalOrvosi Hetilap
Volume158
Issue number6
DOIs
Publication statusPublished - febr. 1 2017

Fingerprint

B-Cell Chronic Lymphocytic Leukemia
Mutation
Sequence Deletion
Mutation Rate
Exons
Medicine

Keywords

  • Chronic lymphocytic leukaemia
  • Targeted therapy
  • TP53

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Viktória, F., Dóra, M., Béla, K., Attila, K. P., Demeter, J., Tímea, G. P., ... Csaba, B. (2017). A TP53-mutáció-analízis jelentosége krónikus lymphocytás leukaemiában. Orvosi Hetilap, 158(6), 220-228. https://doi.org/10.1556/650.2017.30656

A TP53-mutáció-analízis jelentosége krónikus lymphocytás leukaemiában. / Viktória, Fésüs; Dóra, Marosvári; Béla, Kajtár; Attila, Király Péter; Demeter, J.; Tímea, Gurbity Pálfi; Miklós, Egyed; Márk, Plander; Péter, Farkas; Zoltán, Mátrai; Matolcsy, A.; Csaba, Bödör.

In: Orvosi Hetilap, Vol. 158, No. 6, 01.02.2017, p. 220-228.

Research output: Article

Viktória, F, Dóra, M, Béla, K, Attila, KP, Demeter, J, Tímea, GP, Miklós, E, Márk, P, Péter, F, Zoltán, M, Matolcsy, A & Csaba, B 2017, 'A TP53-mutáció-analízis jelentosége krónikus lymphocytás leukaemiában', Orvosi Hetilap, vol. 158, no. 6, pp. 220-228. https://doi.org/10.1556/650.2017.30656
Viktória, Fésüs ; Dóra, Marosvári ; Béla, Kajtár ; Attila, Király Péter ; Demeter, J. ; Tímea, Gurbity Pálfi ; Miklós, Egyed ; Márk, Plander ; Péter, Farkas ; Zoltán, Mátrai ; Matolcsy, A. ; Csaba, Bödör. / A TP53-mutáció-analízis jelentosége krónikus lymphocytás leukaemiában. In: Orvosi Hetilap. 2017 ; Vol. 158, No. 6. pp. 220-228.
@article{d2c22275cfaa46739c21a97f79dbcf50,
title = "A TP53-mut{\'a}ci{\'o}-anal{\'i}zis jelentos{\'e}ge kr{\'o}nikus lymphocyt{\'a}s leukaemi{\'a}ban",
abstract = "Introduction: In recent years much progress has been made in the therapy of chronic lymphocytic leukaemia, as the new innovative medicine proved to be effective in managing patients carrying TP53 abnormalities. To identify all these patients, it is essential to screen for both forms of TP53 defects, including both 17p deletions and TP53 mutations. Aim: The aim of this study was to determine the frequency of TP53 mutations and their association with 17p deletions in a large Hungarian cohort of 196 patients suffering from chronic lymphocytic leukaemia. Method: We performed mutation analysis of TP53 (exons 3-10) using Sanger sequencing. Results: TP53 mutations were present in 15.8{\%} of patients, half of which were associated with 17p deletion. By analysing both forms, TP53 defect was identified in 25.4{\%} of the patients. Conclusions: Our study demonstrates that by performing a TP53 mutation analysis, an additional 10{\%} of high-risk patients can be detected.",
keywords = "Chronic lymphocytic leukaemia, Targeted therapy, TP53",
author = "F{\'e}s{\"u}s Vikt{\'o}ria and Marosv{\'a}ri D{\'o}ra and Kajt{\'a}r B{\'e}la and Attila, {Kir{\'a}ly P{\'e}ter} and J. Demeter and T{\'i}mea, {Gurbity P{\'a}lfi} and Egyed Mikl{\'o}s and Plander M{\'a}rk and Farkas P{\'e}ter and M{\'a}trai Zolt{\'a}n and A. Matolcsy and B{\"o}d{\"o}r Csaba",
year = "2017",
month = "2",
day = "1",
doi = "10.1556/650.2017.30656",
language = "Hungarian",
volume = "158",
pages = "220--228",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",
number = "6",

}

TY - JOUR

T1 - A TP53-mutáció-analízis jelentosége krónikus lymphocytás leukaemiában

AU - Viktória, Fésüs

AU - Dóra, Marosvári

AU - Béla, Kajtár

AU - Attila, Király Péter

AU - Demeter, J.

AU - Tímea, Gurbity Pálfi

AU - Miklós, Egyed

AU - Márk, Plander

AU - Péter, Farkas

AU - Zoltán, Mátrai

AU - Matolcsy, A.

AU - Csaba, Bödör

PY - 2017/2/1

Y1 - 2017/2/1

N2 - Introduction: In recent years much progress has been made in the therapy of chronic lymphocytic leukaemia, as the new innovative medicine proved to be effective in managing patients carrying TP53 abnormalities. To identify all these patients, it is essential to screen for both forms of TP53 defects, including both 17p deletions and TP53 mutations. Aim: The aim of this study was to determine the frequency of TP53 mutations and their association with 17p deletions in a large Hungarian cohort of 196 patients suffering from chronic lymphocytic leukaemia. Method: We performed mutation analysis of TP53 (exons 3-10) using Sanger sequencing. Results: TP53 mutations were present in 15.8% of patients, half of which were associated with 17p deletion. By analysing both forms, TP53 defect was identified in 25.4% of the patients. Conclusions: Our study demonstrates that by performing a TP53 mutation analysis, an additional 10% of high-risk patients can be detected.

AB - Introduction: In recent years much progress has been made in the therapy of chronic lymphocytic leukaemia, as the new innovative medicine proved to be effective in managing patients carrying TP53 abnormalities. To identify all these patients, it is essential to screen for both forms of TP53 defects, including both 17p deletions and TP53 mutations. Aim: The aim of this study was to determine the frequency of TP53 mutations and their association with 17p deletions in a large Hungarian cohort of 196 patients suffering from chronic lymphocytic leukaemia. Method: We performed mutation analysis of TP53 (exons 3-10) using Sanger sequencing. Results: TP53 mutations were present in 15.8% of patients, half of which were associated with 17p deletion. By analysing both forms, TP53 defect was identified in 25.4% of the patients. Conclusions: Our study demonstrates that by performing a TP53 mutation analysis, an additional 10% of high-risk patients can be detected.

KW - Chronic lymphocytic leukaemia

KW - Targeted therapy

KW - TP53

UR - http://www.scopus.com/inward/record.url?scp=85013650571&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85013650571&partnerID=8YFLogxK

U2 - 10.1556/650.2017.30656

DO - 10.1556/650.2017.30656

M3 - Article

VL - 158

SP - 220

EP - 228

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

IS - 6

ER -